SearchDictionaryMobileLogin

Mitch Dowsett Selected Research

Breast Neoplasms (Breast Cancer)

10/2008Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
08/2008Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
06/2008Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
05/2008The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
04/2008Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
12/2007Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
10/2007Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
09/2007A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
09/2007The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
08/2007A luminal breast cancer genome atlas: progress and barriers.
08/2007Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.
07/2007Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
04/2007Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
02/2007Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
01/20072-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
01/2007Molecular response to aromatase inhibitor treatment in primary breast cancer.
12/2006The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer.
10/2006Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
09/2006Implications of gene-environment interaction in studies of gene variants in breast cancer: an example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene.
09/2006Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
07/2006Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
07/2006Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
06/2006Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
05/2006The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women.
01/2006Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
01/2006Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
12/2005The biology of steroid hormones and endocrine treatment of breast cancer.
10/2005Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
09/2005Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
08/2005Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
04/2005Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
04/2005Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
01/2005Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
01/2005Deficits in plasma oestradiol measurement in studies and management of breast cancer.
05/2004Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk.
04/2004Adjuvant use of anastrozole in breast cancer.
01/2004Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
11/2003Aromatase inhibitors for breast cancer: lessons from the laboratory.
10/2003Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.
10/2003Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
08/2003Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.
07/2003Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
07/2003Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
06/2003Aromatase inhibitors in breast cancer.
01/2003Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
12/2002Breast cancer: aromatase inhibitors take on tamoxifen.
07/2002Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
02/2002Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
01/2002Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
01/2002Aromatase and its inhibitors: significance for breast cancer therapy.

Articles by Research Topic

Disease

50Breast Neoplasms (Breast Cancer)
10/2008 - 01/2002
9Neoplasms (Cancer)
10/2008 - 03/2002
1Prostatic Neoplasms (Prostate Cancer)
10/2008
1Cardiovascular Diseases (Cardiovascular Disease)
12/2007
1Carcinoma (Carcinomatosis)
07/2006

Drug/Important Bio-Agent (IBA)

12TamoxifenFDA LinkGeneric
05/2008 - 12/2002
8anastrozole (Arimidex)FDA Link
05/2008 - 02/2002
7Aromatase InhibitorsIBA
06/2008 - 12/2002
6Estrogens (Estrogen)FDA Link
10/2008 - 02/2002
6HormonesIBA
10/2008 - 01/2003
5Estradiol (Estrace)FDA LinkGeneric
04/2008 - 01/2005
5Aromatase (CYP19)IBA
01/2007 - 01/2002
4letrozole (Femara)FDA Link
04/2008 - 02/2002
2tipifarnib (R115777)IBA
09/2007 - 07/2003
2Gonadal Steroid Hormones (Sex Hormones)IBA
05/2007 - 01/2006
2trastuzumab (Herceptin)FDA Link
01/2007 - 10/2005
2Phytoestrogens (Phytoestrogen)IBA
01/2005 - 05/2004
1abirateroneIBA
10/2008
1Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA
10/2008
1Goserelin (Zoladex)FDA Link
08/2008
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
05/2008
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2008
1Estrone (Folliculin)FDA Link
04/2008
1Testosterone (Sustanon)FDA LinkGeneric
12/2007
1DNA topoisomerase II alphaIBA
12/2007
1AnthracyclinesIBA
12/2007
1Epidermal Growth Factor Receptor (EGF Receptor)IBA
10/2007
1Farnesyltranstransferase (Farnesyltransferase)IBA
09/2007
1gefitinib (Iressa)FDA Link
09/2007
1Phenobarbital (Luminal)FDA Link
08/2007
1tiboloneIBA
07/2007
1LeptinIBA
04/2007
1IsoflavonesIBA
09/2006
1Sex Hormone-Binding GlobulinIBA
09/2006
1Cyclin D1IBA
07/2006
1Dehydroepiandrosterone SulfateIBA
05/2006
1Dehydroepiandrosterone (DHEA)IBA
05/2006
1Diethylstilbestrol (Stilbestrol)FDA Link
09/2005
1Protein Kinases (Protein Kinase)IBA
04/2005
1Biological Markers (Surrogate Marker)IBA
05/2004
1Selective Estrogen Receptor Modulators (SERM)IBA
10/2003
1LY 353381 (LY353381)IBA
10/2003
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
07/2003
1TransferasesIBA
07/2003
1Complementary DNA (cDNA)IBA
03/2002

Therapy/Procedure

4Drug Therapy (Chemotherapy)
10/2007 - 01/2002
3Adjuvant Chemotherapy
08/2008 - 10/2005
2Chemoprevention
03/2007 - 09/2006
2Neoadjuvant Therapy
08/2005 - 01/2005
1Castration
10/2008
1Lasers (Laser)
10/2003
1Heterologous Transplantation (Xenotransplantation)
10/2003